Emergency room could be the starting point for alcohol addiction treatment

NCT ID NCT05827159

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether giving people with moderate to severe alcohol use disorder a medication called naltrexone (as a pill or injection) right in the emergency department, along with a brief counseling session, helps them follow up with ongoing treatment. All participants receive counseling and a referral, but only some get the medication started in the ED. The main goal is to see if more people engage in alcohol treatment 30 days later.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
naltrexone (pill or injection) plus a brief counseling session
What this could lead to
If successful, this approach could make it easier for people with alcohol use disorder to start treatment right when they are in the emergency department, potentially reducing heavy drinking.
What could go wrong
This is a single trial with 240 participants, and the benefits may not apply to everyone. Naltrexone can cause side effects like nausea or headache, and some people may not respond to the medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse Emergencies

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Yale New Haven Hospital

    RECRUITING

    New Haven, Connecticut, 06520, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.